Lung cancer

7 currently open clinical trials

Osimertinib and bevacizumab versus osimertinib alone for patients with non-small cell lung cancer
ETOP BOOSTER
Anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with lung cancer
EORTC PEARLS
Dosage of a new targeted drug for the treatment of lung cancer
SAKK 19/16
Durvalumab in patients with advanced lung cancer and poor general state of health
SAKK 19/17
Single arm phase II trial evaluating the activity of Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
ETOP ALERT
Targeted therapy beyond progression with or without dose-intensified radiotherapy in oligo-progressive disease (OPD) in oncogene addicted lung tumours
EORTC HALT
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment in advanced malignant pleural mesothelioma
ETOP BEAT-meso
All cancer types